###### Significance of this study

What is already known about this subject?
=========================================

-   Comorbid illnesses, such as type 2 diabetes mellitus (T2DM), are risk factors for any type of pneumonia.

What are the new findings?
==========================

-   Incidence of all the types of pneumonia analyzed was significantly higher in patients with T2DM than in patients with non-T2DM.

-   In-hospital mortality was significantly lower among patients with T2DM and ventilator-associated pneumonia than matched patients with non-diabetes.

-   Higher mortality rates in patients with diabetes with any pneumonia type were associated with increasing age, presence of comorbidity and dialysis.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Our data suggest that future investigations are necessary to identify preventive programs, protocols and interventions than help to prevent and mitigate this burdensome complication.

Introduction {#s1}
============

Pneumonia is a major global health problem and a significant cause of morbidity and mortality worldwide.[@R1] Several studies have found that the incidence of community-acquired pneumonia (CAP) is increasing and is highly influenced by age and comorbidities.[@R2] Quan *et al* in Oxfordshire, UK, found that from 2009 to 2014, the number of hospital admissions of patients with CAP increased by ≈9% per year.[@R5] Among infections acquired during hospitalization, hospital-acquired pneumonia (HAP) is the most frequent, accounting for an estimated 16.6% of all hospital infections.[@R6]

The investigations over the last years have been mainly centered on ventilator-associated pneumonia (VAP), and this has resulted in improved methods for prevention and management, which has reduced the incidence, mortality and morbidity caused by this infection.[@R7] However, some hospitalized patients develop non-ventilator hospital-acquired pneumonia (NV-HAP). Giuliano *et al* analyzed the US National Inpatient Sample dataset and described that NV-HAP causes an increase in the costs, length of hospital stays and mortality of hospitalized patients.[@R9]

It has been reported that comorbid illnesses, such as type 2 diabetes mellitus (T2DM), are risk factors for any type of pneumonia.[@R10] The specific role of T2DM has been previously identified.[@R11] Recently, Campling *et al* found that patients with T2DM have a significantly higher risk of hospital admission for CAP (OR 1.18; 95% CI 1.13 to 1.23).[@R13] Reasons for the higher risk among patients with diabetes include impaired immunity as a result of hyperglycemia, altered lung function and greater risk of aspiration.[@R14] However, the results are not conclusive, and Vardakas *et al* reported that for HAP, diabetes is not a risk factor.[@R15]

Diabetes is a major public health problem in Spain. According to the Base de Datos Clínicos de Atención Primaria/Primary Care Clinical Database (BDCAP) that covers 4.7 million patients attended at Spanish primary care centers, the overall prevalence of diabetes in year 2016 was of 6.7% (7.3% for men and 6.1% for women). The results of the Spanish National Health Survey conducted in year 2017 (SNHS2017) showed a self-reported prevalence of 7.8% for those aged 15 years or over. Finally, the Di\@bet.es Study, a national study in Spain including 5072 individuals aged ≥18 years, found that the overall prevalence of diabetes mellitus adjusted for age and sex was 13.8% (95% CI 12.8% to 14.7%), of which 6.0% had unknown diabetes (95% CI 5.4% to 6.7%).[@R16]

Given this background of contrasting findings, in this study, we aim to (1) examine the incidence, characteristics and outcomes of CAP, VAP and NV-HAP among patients with or without T2DM in Spain in 2016--2017; (2) compare in-hospital outcomes of CAP, VAP and NV-HAP between patients with and without T2DM and (3) identify factors associated with in-hospital mortality (IHM) after CAP, VAP and NV-HAP among patients with T2DM.

Research design and methods {#s2}
===========================

Design, setting and participants {#s2-1}
--------------------------------

This observational retrospective epidemiological study was conducted using the Hospital Discharge Records of the Spanish National Health System (RAE-CMBD, *Registro de Actividad de Atención Especializada-Conjunto Mínimo Básico de Datos*) from January 1, 2016 to December 31, 2017. The RAE-CMBD includes up to 20 discharge diagnoses and procedures performed during the hospital stay. Coding was performed using the International Classification of Disease, 10th Revision (ICD-10).[@R19] Each discharge diagnosis has a "Present on Admission (POA)" indicator assigned according to the ICD-10, Clinical Modification (ICD-10-CM) Official Guidelines for Coding and Reporting (<https://icdlist.com/icd-10/guidelines/>). The reporting options and definitions for POA are "Y" (present at admission); "N" (not present at admission); "U" (lack documentation to determine presence at admission); "W" (provider is unable to clinically determine if the condition was present) and unreported/not used.

The study population comprised all hospital admissions of patients aged 40 years or older who were hospitalized with a pneumonia diagnosis. We defined CAP as any hospitalization that included any of the following conditions: (1) any ICD-10 code from J12 to J18 as primary diagnosis with a POA indicator of "Y" and (2) any ICD-10 code from J12 to J18 in any of the secondary diagnosis fields (2-20) and with a POA indicator of "Y." VAP is defined as any hospitalization with a diagnosis ICD-10 code J95.851 in any diagnosis position and a POA indicator of "N" (not present at admission). NV-HAP is characterized by pneumonia that was not present when the patient was admitted to the hospital and that was not associated with the use of mechanical ventilation during hospitalization. We identified NV-HAP in those patients with any ICD-10 codes from J12 to J18 in any diagnosis position and with a POA indicator coded as "N" who had a hospitalization ≥48 hours. To avoid the possibility that pneumonia was associated with the use of ventilatory support, patients with codes for non-invasive or invasive mechanical ventilation in any procedure fields were excluded from the NV-HAP group.

For study purposes, we excluded hospitalized patients with influenza-related pneumonia (ICD-10 codes: J09, J10, J11), those with aspiration pneumonia (J69, J69.0, J69.1, J69.8) and those with ICD-10 codes from J12 to J18 in any diagnosis fields and with a POA indicator coded as "U," "W" or "unreported/not used."

We grouped admissions by diabetes status as follows: "patients with T2DM" if any E11.x ICD-10 codes were recorded in any diagnosis position (1-20) or "patients without T2DM" if no codes for T2DM appeared in any diagnostic position. We excluded people with type 1 diabetes mellitus (T1DM; ICD-10 codes: E10.x) in any diagnosis position.

Study variables {#s2-2}
---------------

Our main study variables are the incidence, IHM and length of hospital stay (LOHS). Covariates include age, sex, comorbidities and therapeutic procedures.

Comorbidity was assessed using the Charlson Comorbidity Index (CCI).[@R20] The ICD-10 codes for the CCI conditions in any of the discharge diagnosis are those described by Quan *et al*.[@R20] We provide results for each condition included in the CCI and a sum of the number of these conditions.

The RAE-CMBD includes a variable with the Diagnosis-Related Groups categorized as Medical/Surgical/Other that was used to identify patients who underwent any type of surgical procedure during their hospital admission.[@R19]

We specifically identified the following procedures: axial CT of the thorax, bronchial fibroscopy, non-invasive mechanical ventilation, invasive mechanical ventilation and dialysis. Additionally, a diagnosis of pressure ulcer was identified in any diagnosis field. The ICD-10 codes used for this purpose are shown in [online supplementary table 1](#SP1){ref-type="supplementary-material"}.
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The pathogens codified in any diagnosis field among patients with pneumonia were identified with the ICD-10 codes: A48.1 for *Legionella*; B37.1 for candidiasis; B44.9 for *Aspergillus*; J13 for *Streptococcus pneumoniae*; J14 for *Haemophilus influenzae*; J15 for *Klebsiella pneumoniae*; J15.1 for *Pseudomonas aeruginosa*; J15.211 and J15.212 for *Staphylococcus aureus*; J15.4 for non-specified *Streptococcus*; J15.5 for *Escherichia coli* and J15.6 for other Gram-negative bacteria. Regarding pathogen detections, according to the RAE-CMBD methodology, only pathogens that are laboratory confirmed can be codified.[@R19]

Propensity score matching (PSM) method {#s2-3}
--------------------------------------

We used propensity scores (PSs) to obtain unbiased matched populations of patients with and without T2DM.[@R21] The PSM method consists of selecting patients with T2DM and non-T2DM with the same or similar PS obtained with multivariable logistic regression so we match the distribution of confounding factors for both populations.[@R22] The variables included in the PSM model were sex, age, CCI and whether a surgery was performed.

Statistical methods {#s2-4}
-------------------

The incidence rates of hospital admissions for the three types of pneumonia according to the presence of T2DM were calculated per 100 000 individuals. We used data from the 2016/2017 Spanish National Health Survey and Spanish National Institute of Statistics to estimate the number of people with T2DM in Spain by sex and age group.[@R17]

Categorical variables are shown as proportions, and continuous variables are shown as the means with SD. To compare patients with and without T2DM, the statistical tests conducted for continuous variables were the t-test (age) or Mann-Whitney test (LOHS); for categorical variables, we used the χ^2^ test. To assess differences in the incidence rates between patients with and without T2DM, we used age-adjusted and sex-adjusted Poisson regression.

McNemar's test and paired t-test were used to compare study groups after PSM.[@R25]

Multivariable logistic regression analyses were constructed to identify predictors of IHM among patients with T2DM.

To conduct the multivariable regression models (logistic and Poisson), the following steps were done: (1) Bivariate analysis of each variable. (2) Selection of variables to be included in the multivariable analysis. We included all variables with a significant association (p\<0.10) in the bivariate test and those identified as important in the literature search. (3) The importance of each variable included in the model was verified using the Wald statistic and successive models were compared with the previous using the Likelihood Ratio (LR) test. (4) Once the model was obtained, we analyzed possible linearity between variables and checked for interactions.

The results of multivariable models are shown as incidence rate ratios (IRRs) with 95% CIs for Poisson regression and as ORs with their 95% CIs for logistic regression.

Stata V.14 (Stata, College Station, Texas, USA) was used for data analysis.

Ethical aspects {#s2-5}
---------------

According to the Spanish legislation, as we used the RAE-CMBD, a de-identified retrospective public access database that is provided freely to all investigators by the Spanish Ministry of Health, it was not necessary to obtain approval from an ethics committee.

Results {#s3}
=======

Incidence of CAP, VAP and NV-HAP according to T2DM status {#s3-1}
---------------------------------------------------------

We analyzed 245 221 hospitalized patients aged ≥40 years with pneumonia in Spain (2016--2017). CAP diagnosis was identified in 227 524 patients (27.67% with T2DM), VAP diagnosis was identified in 2752 (18.31% with T2DM) and 14 945 patients were identified as having an NV-HAP diagnosis (25.75% with T2DM).

The crude incidence of CAP was significantly higher in people with T2DM than in non-diabetic people (2057.58 cases per 1 00 000 T2DM population vs 726.82 cases per 100 000 non-T2DM population; p\<0.001). Crude incidences of VAP and NV-HAP coding were not significantly higher in patients with T2DM than in patients without T2DM ([table 1](#T1){ref-type="table"}). However, after age-adjusted and sex-adjusted Poisson regression, we found that the incidence of all the types of pneumonia analyzed was higher among patients with T2DM than among those without (CAP: IRR 1.44, 95% CI 1.42 to 1.45; VAP: IRR 1.24, 95% CI 1.12 to 1.37 and NV-HAP: IRR 1.38, 95% CI 1.33 to 1.44).

###### 

Incidence, clinical characteristics and in-hospital outcomes of patients hospitalized with community-acquired pneumonia (CAP), ventilator-associated pneumonia (VAP) and non-ventilator hospital-acquired pneumonia (NV-HAP) in Spain (2016--2017)

                                         CAP              P value          VAP       P value         NV-HAP          P value                                   
  -------------------------------------- ---------------- ---------------- --------- --------------- --------------- --------- --------------- --------------- ---------
  N                                      62 962           164 562          NA        504             2248            NA        3849            11 096          NA
  Incidence per 100 000 subjects         2057.58          726.82           \<0.001   16.47           9.93            0.725     125.78          49.01           0.158
  Female sex, n (%)                      23 954 (38.05)   67 937 (41.28)   \<0.001   146 (28.97)     669 (29.76)     0.725     1334 (34.66)    3986 (35.92)    0.158
  Age, mean (SD)                         78.09 (10.4)     75.47(14)        \<0.001   67.67 (9.68)    63.22 (11.82)   \<0.001   76.14 (10.43)   72.64 (13.63)   \<0.001
  40--64 years, n (%)                    7124 (11.31)     36 745 (22.33)   \<0.001   187 (37.1)      1191 (52.98)    \<0.001   550 (14.29)     3110 (28.03)    \<0.001
  65--74 years, n (%)                    13 182 (20.94)   28 823 (17.51)   \<0.001   191 (37.9)      602 (26.78)     \<0.001   950 (24.68)     2372 (21.38)    \<0.001
  ≥75 years, n (%)                       42 656 (67.75)   98 994 (60.16)   \<0.001   126(25)         455 (20.24)     \<0.001   2349 (61.03)    5614 (50.59)    \<0.001
  CCI, mean (SD)                         1.44 (1.08)      1.17(1)          \<0.001   1.28 (0.97)     1.09 (0.96)     \<0.001   1.72 (1.13)     1.41 (1.04)     \<0.001
  Myocardial infarction, n (%)           4372 (6.94)      6270 (3.81)      \<0.001   68 (13.49)      215 (9.56)      0.009     421 (10.94)     676 (6.09)      \<0.001
  Congestive heart failure, n (%)        17 991 (28.57)   32 903 (19.99)   \<0.001   115 (22.82)     330 (14.68)     \<0.001   1247 (32.4)     2522 (22.73)    \<0.001
  Peripheral vascular disease, n (%)     4739 (7.53)      7591 (4.61)      \<0.001   41 (8.13)       140 (6.23)      0.118     446 (11.59)     817 (7.36)      \<0.001
  Cerebrovascular disease, n (%)         5480 (8.7)       9722 (5.91)      \<0.001   105 (20.83)     490 (21.8)      0.635     689 (17.9)      1521 (13.71)    \<0.001
  Dementia, n (%)                        6270 (9.96)      15 363 (9.34)    \<0.001   3 (0.6)         18 (0.8)        0.632     291 (7.56)      645 (5.81)      \<0.001
  COPD, n (%)                            21 455 (34.08)   53 931 (32.77)   \<0.001   84 (16.67)      310 (13.79)     0.096     965 (25.07)     2533 (22.83)    0.005
  Rheumatoid disease, n (%)              1489 (2.36)      4332 (2.63)      \<0.001   5 (0.99)        26 (1.16)       0.752     74 (1.92)       256 (2.31)      0.162
  Peptic ulcer, n (%)                    350 (0.56)       980 (0.6)        0.267     16 (3.17)       49 (2.18)       0.184     67 (1.74)       237 (2.14)      0.135
  Mild liver disease, n (%)              3107 (4.93)      7823 (4.75)      0.071     31 (6.15)       121 (5.38)      0.495     200 (5.2)       625 (5.63)      0.307
  Hemiplegia or paraplegia, n (%)        441 (0.7)        1394 (0.85)      \<0.001   39 (7.74)       242 (10.77)     0.043     195 (5.07)      567 (5.11)      0.915
  Renal disease, n (%)                   16 936 (26.9)    25 075 (15.24)   \<0.001   72 (14.29)      150 (6.67)      \<0.001   1097 (28.5)     1699 (15.31)    \<0.001
  Cancer, n (%)                          5035 (8)         15 536 (9.44)    \<0.001   32 (6.35)       188 (8.36)      0.132     530 (13.77)     2004 (18.06)    \<0.001
  Moderate/severe liver disease, n (%)   686 (1.09)       1595 (0.97)      \<0.010   17 (3.37)       83 (3.69)       0.729     149 (3.87)      361 (3.25)      0.069
  Metastatic cancer, n (%)               2265 (3.6)       8631 (5.24)      \<0.001   16 (3.17)       64 (2.85)       0.692     239 (6.21)      1139 (10.26)    \<0.001
  AIDS, n (%)                            161 (0.26)       2008 (1.22)      \<0.001   0 (0)           14 (0.62)       0.076     8 (0.21)        86 (0.78)       \<0.001
  Undergone surgery, n (%)               1894 (3.01)      5504 (3.34)      \<0.001   371 (73.61)     1734 (77.14)    0.092     1447 (37.59)    5061 (45.61)    \<0.001
  LOHS, mean (SD)                        9.78 (8.09)      9.72 (9.11)      0.333     47.41 (39.58)   53.42 (47.78)   0.009     27.54 (22.12)   30.83 (28.84)   \<0.001
  IHM, n (%)                             8024 (12.74)     21 649 (13.16)   0.009     220 (43.65)     846 (37.63)     0.012     1117 (29.02)    3120 (28.12)    0.285

CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; IHM, in-hospital mortality; LOHS, length of hospital stay; NA, Not adequate; T2DM, type 2 diabetes mellitus.

Clinical characteristics and in-hospital outcomes of patients hospitalized with CAP, VAP and NV-HAP according to T2DM status {#s3-2}
----------------------------------------------------------------------------------------------------------------------------

In both groups studied, men represented a higher proportion of patients with CAP than women (61.95% and 58.72% for patients with and without T2DM, respectively, p\<0.001). Overall, the mean age was significantly higher among patients with T2DM (78.09; SD=10.4 years) than non-T2DM (75.47; SD=14 years), and patients with T2DM also had a higher mean CCI (p\<0.001). Specifically, there was a higher prevalence of congestive heart failure (28.57% vs 19.99%), peripheral vascular disease (7.53% vs 4.61%), cerebrovascular disease (8.7% vs 5.91%), dementia (9.96% vs 9.34%), chronic obstructive pulmonary disease (COPD) (34.08% vs 32.77%), renal disease (26.9% vs 15.24%), and moderate/severe liver disease (1.09% vs 0.97%), and the prevalence of myocardial infarction was two times higher (all p values \<0.001). During hospitalization, patients with diabetes underwent surgery (3.01%) significantly less often than patients with non-diabetes (3.34%). The mean LOHS was approximately 9.7 days in patients with both T2DM and non-T2DM. The crude IHM was 12.74% for patients with T2DM and 13.16% for people with non-diabetes (p=0.009) ([table 1](#T1){ref-type="table"}).

In patients with VAP, there was a significant male predominance (71.03% and 70.24% for T2DM and non-T2DM, respectively). Overall, patients with T2DM were significantly older than those without diabetes (67.67 vs 63.22 years; p\<0.001) and had a higher mean CCI (1.28±0.97 for T2DM vs 1.09±0.96 non-T2DM; p\<0.001). Specifically, patients with T2DM had a higher prevalence of myocardial infarction (13.49% vs 9.56%; p=0.009), congestive heart failure (22.82% vs 14.68%; p\<0.001) and renal disease (14.29% vs 6.67%; p\<0.001). The overall mean LOHS was significantly lower in patients with T2DM (47.41 vs 53.42 days; p=0.009). Crude IHM was 43.65% for patients with T2DM and 37.63% for patients with non-T2DM (p=0.012) ([table 1](#T1){ref-type="table"}).

As described in the other two types of pneumonia studied, NV-HAP was more common among men in addition to patients with diabetes (65.34% and 64.08% for patients with T2DM and non-diabetes, respectively). The mean age was higher among patients with T2DM (76.14 vs 72.64 years; p\<0.001), and they also had a higher mean CCI (1.72 vs 1.41; p\<0.001). Specifically, there was a higher prevalence of myocardial infarction (10.94% vs 6.09%; p\<0.001), congestive heart failure (32.4% vs 22.73%; p\<0.001), peripheral vascular disease (11.59% vs 7.36%; p\<0.001), cerebrovascular disease (17.9% vs 13.71%; p\<0.001), dementia (7.56% vs 5.81%; p\<0.001), COPD (25.07% vs 22.83%; p=0.005) and renal disease (28.5% vs 15.31%; p\<0.001). Patients with T2DM included in our investigation had undergone surgery significantly less frequently than patients with non-diabetes (37.59% vs 45.61%; p\<0.001). The mean LOHS was significantly lower in patients with T2DM than in patients with non-T2DM (27.54 vs 30.83 days; p\<0.001). The crude IHM was approximately 29% in both groups ([table 1](#T1){ref-type="table"}).

Distribution of study covariates among patients with and without T2DM hospitalized with CAP, VAP and NV-HAP after PSM {#s3-3}
---------------------------------------------------------------------------------------------------------------------

Shown in [table 2](#T2){ref-type="table"} are the characteristics of patients admitted with CAP and T2DM as well as those of their PSM non-diabetic controls.

###### 

Distribution of study covariates and hospital outcomes of patients with and without T2DM hospitalized with community-acquired pneumonia in Spain (2016--2017), after propensity score matching

                                               T2DM             No T2DM          P value
  -------------------------------------------- ---------------- ---------------- ---------
  Male sex, n (%)                              39 008 (61.95)   39 351 (62.5)    0.046
  Female sex, n (%)                            23 954 (38.05)   23 611 (37.5)    
  Age, mean (SD)                               78.09 (10.4)     78.99 (11.05)    \<0.001
  40--64 years, n (%)                          7124 (11.31)     7123 (11.31)     \<0.001
  65--74 years, n (%)                          13 182 (20.94)   11 339 (18.01)   
  ≥75 years, n (%)                             42 656 (67.75)   44 500 (70.68)   
  CCI, mean (SD)                               1.44 (1.08)      1.41 (1.07)      \<0.001
  Myocardial infarction, n (%)                 4372 (6.94)      4020 (6.38)      \<0.001
  Congestive heart failure, n (%)              17 991 (28.57)   17 795 (28.26)   0.221
  Peripheral vascular disease, n (%)           4739 (7.53)      4441 (7.05)      0.001
  Cerebrovascular disease, n (%)               5480 (8.7)       5191 (8.24)      0.003
  Dementia, n (%)                              6270 (9.96)      6586 (10.46)     0.003
  COPD, n (%)                                  21 455 (34.08)   21 765 (34.57)   0.066
  Rheumatoid disease, n (%)                    1489 (2.36)      1312 (2.08)      0.001
  Peptic ulcer, n (%)                          350 (0.56)       252 (0.4)        \<0.001
  Mild liver disease, n (%)                    3107 (4.93)      2891 (4.59)      0.004
  Hemiplegia or paraplegia, n (%)              441 (0.7)        348 (0.55)       0.001
  Renal disease, n (%)                         16 936 (26.9)    16 450 (26.13)   0.002
  Cancer, n (%)                                5035(8)          4855 (7.71)      0.059
  Moderate/severe liver disease, n (%)         686 (1.09)       594 (0.94)       0.010
  Metastatic cancer, n (%)                     2265 (3.6)       2007 (3.19)      \<0.001
  AIDS, n (%)                                  161 (0.26)       140 (0.22)       0.226
  Undergone surgery, n (%)                     1894 (3.01)      1689 (2.68)      0.001
  Axial CT of thorax, n (%)                    3856 (6.12)      4108 (6.52)      0.004
  Bronchial fibroscopy, n (%)                  515 (0.82)       580 (0.92)       0.049
  Non-invasive mechanical ventilation, n (%)   1466 (2.33)      1270 (2.02)      \<0.001
  Invasive mechanical ventilation, n (%)       1285 (2.04)      1309 (2.08)      0.634
  Dialysis, n (%)                              857 (1.36)       737 (1.17)       0.002
  Pressure ulcer, n (%)                        1805 (2.87)      1692 (2.69)      0.053
  LOHS, mean (SD                               9.78 (8.09)      9.77 (8.39)      0.956
  IHM, n (%)                                   8024 (12.74)     8917 (14.16)     \<0.001

CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; IHM, in-hospital mortality; LOHS, length of hospital stay; T2DM, type 2 diabetes mellitus.

Patients with T2DM had significantly higher rates of non-invasive mechanical ventilation and dialysis (2.33% vs 2.02%; p\<0.001 and 1.36% vs 1.17%; p=0.002). However, patients with T2DM had lower rates of axial CT of the thorax (6.12% vs 6.52%; p=0.004) and bronchial fibroscopy (0.82% vs 0.92%; p=0.049). After PSM, the IHM during admission for CAP was 12.74% in patients with T2DM and 14.16% in matched controls (p\<0.001) ([table 2](#T2){ref-type="table"}).

After PSM, the prevalence of *S. pneumoniae* (7.19% vs 7.79%; p\<0.001) and that of *P. aeruginosa* (0.96% vs 1.12%; p=0.004) was lower among patients with T2DM ([online supplementary table 2](#SP1){ref-type="supplementary-material"}).

In patients with VAP ([table 3](#T3){ref-type="table"}), when we compared patients with T2DM with matched controls after PSM, we found significantly lower rates of axial CT in the people with T2DM (5.56% vs 9.52%; p=0.017). The mean LOHS was 47.41±39.58 days among patients with T2DM and 53.52±51.18 days among matched controls (p=0.034) ([table 3](#T3){ref-type="table"}). The IHM was not significantly different between those with and without T2DM (43.65% vs 41.87%; p=0.567).

###### 

Distribution of study covariates and hospital outcomes of patients with and without T2DM hospitalized with ventilator-associated pneumonia in Spain (2016--2017), after propensity score matching

                                         T2DM            No T2DM         P value
  -------------------------------------- --------------- --------------- ---------
  Male sex, n (%)                        358 (71.03)     359 (71.23)     0.945
  Female sex, n (%)                      146 (28.97)     145 (28.77)     
  Age, mean (SD)                         67.67 (9.68)    68.25 (10.48)   0.367
  40--64 years, n (%)                    187 (37.1)      167 (33.13)     0.178
  65--74 years, n (%)                    191 (37.9)      186 (36.9)      
  ≥75 years, n (%)                       126 (25)        151 (29.96)     
  CCI, mean (SD)                         1.28 (0.97)     1.22(1)         0.370
  Myocardial infarction, n (%)           68 (13.49)      69 (13.69)      0.927
  Congestive heart failure, n (%)        115 (22.82)     111 (22.02)     0.763
  Peripheral vascular disease, n (%)     41 (8.13)       37 (7.34)       0.637
  Cerebrovascular disease, n (%)         105 (20.83)     88 (17.46)      0.174
  Dementia, n (%)                        3 (0.6)         4 (0.79)        0.704
  COPD, n (%)                            84 (16.67)      78 (15.48)      0.607
  Rheumatoid disease, n (%)              5 (0.99)        3 (0.6)         0.478
  Peptic ulcer, n (%)                    16 (3.17)       13 (2.58)       0.572
  Mild liver disease, n (%)              31 (6.15)       40 (7.94)       0.268
  Hemiplegia or paraplegia, n (%)        39 (7.74)       37 (7.34)       0.811
  Renal disease, n (%)                   72 (14.29)      64 (12.7)       0.461
  Cancer, n (%)                          32 (6.35)       40 (7.94)       0.328
  Moderate/severe liver disease, n (%)   17 (3.37)       15 (2.98)       0.719
  Metastatic cancer, n (%)               16 (3.17)       17 (3.37)       0.860
  AIDS, n (%)                            0 (0)           0 (0)           NA
  Undergone surgery, n (%)               371 (73.61)     381 (75.6)      0.469
  Axial CT of thorax, n (%)              28 (5.56)       48 (9.52)       0.017
  Bronchial fibroscopy, n (%)            28 (5.56)       29 (5.75)       0.892
  Dialysis, n (%)                        86 (17.06)      76 (15.08)      0.391
  Pressure ulcer, n (%)                  54 (10.71)      50 (9.92)       0.679
  LOHS, mean (SD)                        47.41 (39.58)   53.52 (51.18)   0.034
  IHM, n (%)                             220 (43.65)     211 (41.87)     0.567

CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; IHM, in-hospital mortality; LOHS, length of hospital stay; NA, Not adequate; T2DM, type 2 diabetes mellitus.

The prevalence of *S. aureus* was lower among patients with T2DM than among matched controls (0.99% vs 3.37%; p=0.010) ([online supplementary table 2](#SP1){ref-type="supplementary-material"}).

After PSM, when comparing patients with T2DM with matched controls who had an episode of NV-HAP ([table 4](#T4){ref-type="table"}), we found that pressure ulcers (6.42% vs 5.04%; p=0.009) were more frequently identified among those without T2DM ([table 4](#T4){ref-type="table"}). No significant differences were found regarding LOHS (27.54 days vs 28.18 days; p=0.394) or IHM (29.02% vs 29.75%; p=0.484).

###### 

Distribution of study covariates and hospital outcomes of patients with and without T2DM hospitalized with non-ventilator hospital-acquired pneumonia in Spain (2016--2017), after propensity score matching

                                         T2DM            No T2DM         P value
  -------------------------------------- --------------- --------------- ---------
  Male sex, n (%)                        2515 (65.34)    2485 (64.56)    0.474
  Female sex, n (%)                      1334 (34.66)    1364 (35.44)    
  Age, mean (SD)                         76.14 (10.43)   76.8 (12.05)    0.010
  40--64 years, n (%)                    550 (14.29)     637 (16.55)     \<0.001
  65--74 years, n (%)                    950 (24.68)     751 (19.51)     
  ≥75 years, n (%)                       2349 (61.03)    2461 (63.94)    
  CCI, mean (SD)                         1.72 (1.13)     1.67 (1.15)     0.036
  Myocardial infarction, n (%)           421 (10.94)     402 (10.44)     0.483
  Congestive heart failure, n (%)        1247 (32.4)     1224 (31.8)     0.574
  Peripheral vascular disease, n (%)     446 (11.59)     420 (10.91)     0.348
  Cerebrovascular disease, n (%)         689 (17.9)      681 (17.69)     0.812
  Dementia, n (%)                        291 (7.56)      297 (7.72)      0.797
  COPD, n (%)                            965 (25.07)     964 (25.05)     0.979
  Rheumatoid disease, n (%)              74 (1.92)       65 (1.69)       0.441
  Peptic ulcer, n (%)                    67 (1.74)       74 (1.92)       0.552
  Mild liver disease, n (%)              200 (5.2)       186 (4.83)      0.465
  Hemiplegia or paraplegia, n (%)        195 (5.07)      169 (4.39)      0.163
  Renal disease, n (%)                   1097 (28.5)     1050 (27.28)    0.232
  Cancer, n (%)                          530 (13.77)     516 (13.41)     0.641
  Moderate/severe liver disease, n (%)   149 (3.87)      156 (4.05)      0.683
  Metastatic cancer, n (%)               239 (6.21)      200 (5.2)       0.055
  AIDS, n (%)                            8 (0.21)        5 (0.13)        0.405
  Undergone surgery, n (%)               1447 (37.59)    1461 (37.96)    0.742
  Axial CT of thorax, n (%)              313 (8.13)      313 (8.13)      1.000
  Bronchial fibroscopy, n (%)            49 (1.27)       40 (1.04)       0.370
  Dialysis, n (%)                        214 (5.56)      199 (5.17)      0.448
  Pressure ulcer, n (%)                  247 (6.42)      194 (5.04)      0.009
  LOHS, mean (SD)                        27.54 (22.12)   28.18 (23.79)   0.394
  IHM, n (%)                             1117 (29.02)    1145 (29.75)    0.484

CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; IHM, in-hospital mortality; LOHS, length of hospital stay; T2DM, type 2 diabetes mellitus.

As shown in [online supplementary table 2](#SP1){ref-type="supplementary-material"}, the prevalence of *H. influenzae* was lower among patients with T2DM (0.55% vs 0.94%; p=0.046).

Multivariable logistic regression analysis of the factors associated with IHM among patients with T2DM {#s3-4}
------------------------------------------------------------------------------------------------------

[Table 5](#T5){ref-type="table"} shows the results of the multivariable analysis of the factors associated with IHM after CAP, VAP and NV-HAP among patients with T2DM. Older age and dialysis were factors associated with IHM in the three types of pneumonia analyzed.

###### 

Multivariable analysis of factors associated with in-hospital mortality during admissions for community-acquired pneumonia (CAP), ventilator-associated pneumonia (VAP) and non-ventilator hospital-acquired pneumonia (NV-HAP) among patients with T2DM

                                        CAP                   VAP                   NV-HAP
  ------------------------------------- --------------------- --------------------- ---------------------
  Female sex                            1.01 (0.96 to 1.07)   1.95 (1.28 to 2.96)   1.04 (0.89 to 1.21)
  40--64 years                          1                     1                     1
  65--74 years                          1.5 (1.34 to 1.68)    1.58 (1.01 to 2.46)   1.45 (1.12 to 1.87)
  ≥75 years                             2.91 (2.62 to 3.23)   2.55 (1.54 to 4.21)   1.96 (1.54 to 2.5)
  Myocardial infarction                                       1.98 (1.14 to 3.45)   
  Congestive heart failure              1.25 (1.19 to 1.32)                         1.21 (1.03 to 1.41)
  Peripheral vascular disease           1.53 (1.41 to 1.65)                         1.47 (1.23 to 1.77)
  Dementia                              2.08 (1.94 to 2.23)                         
  COPD                                  0.66 (0.63 to 0.7)    2.03 (1.22 to 3.38)   
  Hemiplegia or paraplegia              2.25 (1.8 to 2.82)                          
  Renal disease                         1.11 (1.05 to 1.18)                         
  Cancer                                1.97 (1.82 to 2.14)                         1.33 (1.08 to 1.65)
  Moderate/severe liver disease         2.07 (1.69 to 2.54)                         1.61 (1.11 to 2.32)
  Metastatic cancer                     4.87 (4.4 to 5.4)                           2.33 (1.75 to 3.1)
  Axial CT of thorax                    0.64 (0.56 to 0.72)                         
  Non-invasive mechanical ventilation   2.15 (1.88 to 2.46)                          
  Invasive mechanical ventilation       4.59 (3.94 to 5.34)                          
  Dialysis                              2.01 (1.68 to 2.4)    2.09 (1.26 to 3.47)   1.77 (1.31 to 2.4)
  Pressure ulcers                       2.5 (2.24 to 2.78)                          1.65 (1.26 to 2.17)
  *Streptococcus pneumoniae*            0.55 (0.49 to 0.61)                         
  *Haemophilus influenzae*              0.26 (0.16 to 0.41)                         
  Undergone surgery                                           0.62 (0.41 to 0.96)   0.73 (0.62 to 0.86)

COPD, chronic obstructive pulmonary disease; T2DM, type 2 diabetes mellitus.

The presence of congestive heart failure, peripheral vascular disease, cancer, moderate/severe liver disease and metastatic cancer increased the probability of dying in patients with CAP and NV-HAP. The presence of pressure ulcers was associated with IHM in patients with CAP and NV-HAP.

The presence of hemiplegia or paraplegia increased the probability of dying in patients with CAP. COPD was a factor associated with IHM in patients with VAP, whereas it was associated with lower IHM in patients with CAP.

In patients with CAP, the presence of dementia and renal disease increased the probability of dying. Furthermore, patients who underwent mechanical ventilation (non-invasive and invasive) had a higher risk of IHM. However, patients who underwent axial CT of the thorax had a lower risk of dying, and the presence of *S. pneumoniae* and *H. influenzae* were also associated with lower mortality.

In patients with VAP, the risk of IHM was higher in females. In addition, the presence of myocardial infarction was associated with higher IHM.

Previous surgery was a factor associated with lower mortality in patients with VAP and NV-HAP.

Discussion {#s4}
==========

This population-based study showed that the incidence of all types of pneumonia analyzed was significantly higher in patients with T2DM than in patients with non-T2DM.

The incidence of CAP observed in our study is consistent with our earlier findings and with the findings of other authors.[@R26] In the USA, among 46 237 subjects aged \>65 years, it was found that patients with diabetes had a 1.52 (95% CI 1.29 to 1.78) higher risk of CAP than those without this disease.[@R28] In Canada, the IRR for pneumonia was 1.46 times higher (95% CI 1.42 to 1.49) for patients with diabetes.[@R12] In Denmark, a study found that T2DM increased the risk of pneumonia-related hospitalization 1.2-fold.[@R11] They concluded that a longer duration of diabetes and poor glycemic control increase the risk of CAP-related hospitalization.[@R11]

The higher incidence of VAP and NV-HAP in patients with T2DM is consistent with previous Spanish reports.[@R29] Karatas *et al* reported a 1.2-fold increased risk of VAP among diabetes sufferers.[@R31] A longer duration of the disease and poor glycemic control have been associated with a greater risk of VAP, as described for CAP.[@R32]

Surgery is a well-established risk factor for pneumonia.[@R33] A population-based study in Spain reported that patients with T2DM had a 1.21-fold higher risk (IRR, 1.21 95% CI 1.03 to 1.42) of suffering from postoperative pneumonia than those without diabetes and concluded that increased risk in patients with T2DM might be related to longer length of stay and higher rates of readmission.[@R29]

The use of non-invasive mechanical ventilation was higher in patients with diabetes admitted with CAP than in non-diabetic controls. In a study about mechanical ventilation use in 56 158 patients with CAP who received ventilator support, the authors found an increase in the prevalence of comorbidities over time that could partially explain the higher need for ventilatory support.[@R35]

We agree with other authors who found that mechanical ventilation was a strong risk factor for IHM in patients with diabetes with CAP and NV-HAP.[@R26]

Our study supports that patients with T2DM and CAP had significantly higher rates of dialysis use than control patients, and dialysis was a risk factor associated with IHM for the three types of pneumonia analyzed. Similar results have been reported previously, suggesting that altered immune function and greater healthcare contact make dialysis patients an especially susceptible risk group for any type of pneumonia.[@R36]

Regarding the pathogens isolated, *S. pneumoniae* was the most frequent infectious agent among patients with T2DM with CAP. It has been suggested that the increase in coverage of pneumococcal vaccination may in part reduce the role of this pathogen over time.[@R38] In Spain, this vaccine is recommended and provided free of charge for T2DM sufferers and all subjects aged 65 years or older.[@R39]

Among patients with diabetes suffering VAP and NV-HAP, the most frequently isolated pathogens were Gram-negative bacteria, among which *Pseudomonas* was found in 3.97% of patients with VAP and 2.86% of patients with NV-HAP. Similar findings were reported by other authors.[@R40]

The mortality associated with pneumonia seems to be decreasing over time in Spain.[@R42] Our study highlights key differences in IHM. The mortality rate in patients with T2DM with CAP was lower than that in matched controls, and no significant differences were found regarding VAP and NV-HAP in patients with T2DM. These results add important evidence to previous information which indicated that the presence of T2DM was not a risk factor for death during admission for CAP.[@R43] Several studies have suggested that hyperglycemia or comorbid conditions and not diabetes itself are responsible for higher IHM after CAP and HAP.[@R44] Another suggested explanation for the lower mortality among patients with diabetes after CAP is the obesity paradox.[@R26] Furthermore, in our opinion, it is possible that patients with CAP and T2DM are admitted to the hospital and are not sent home with oral treatment more frequently than patients without diabetes with equal clinical severity. This would result in a selection bias that could partly explain the lower IHM among patients with T2DM.

As we expected, older age and comorbidity were factors associated with IHM for the three types of pneumonia analyzed. Different studies highlighted that elderly individuals frequently suffer comorbid conditions, which is a factor associated with poor prognosis.[@R28] Another predictor of higher postoperative mortality was pressure ulcers in patients with CAP and NV-HAP. In the USA, a study using the National Inpatient Sample database from 2008 to 2012 found that among 670 767 patients with pressure ulcers, the pneumonia mortality rate was five times higher (OR 5.08, CI: 5.03 to 5.1; p\<0.001) than that in patients without pressure ulcers.[@R47]

Female sex was a risk factor for mortality in patients with T2DM with VAP. Sharpe *et al* described that the incidence of CAP is lower among women than men, but when women have this disease, they have significantly higher IHM (24% vs 15%; p=0.009). Differences in the type of CAP could justify this finding.[@R48] Similar results have been described by Ali *et al*, confirming the worse prognosis of female patients with VAP.[@R49]

Previous surgery was a factor associated with lower mortality in patients with VAP and NV-HAP. We think that patients with T2DM with older age and worse health status are possibly less likely to undergo surgery, which may have resulted in this association.

The strengths of this study included the use of comprehensive, nationwide, population-based register data. We used a case definition for pneumonia hospitalization with increased specificity by using POA as an indicator assigned according to the ICD-10-CM Guidelines.

Several limitations to our investigation must be considered. First, in our investigation we excluded patients under the age of 40 years. The reasons to do this is that according to data from the BDCAP, the SNHS2017 and a report by the Spanish Society of Epidemiology, the prevalence of T2DM becomes significant in adults aged 40 years or older.[@R16] Prevalence figures for those below 40 years are under 1%.[@R16] Furthermore, the prevalence of T1DM is higher than T2DM in subjects under 40 years; therefore, the risk of misclassification of a patient as T2DM when he really suffers T1DM is higher for those under 40 years. Finally, this age cut-off point has also been used by previous studies conducted to analyze pneumonia among patients with T2DM.[@R26]

Second, our data source (RAE-CMBD) is limited by the lack of laboratory or radiology results, treatments, such as information on oxygen or corticoids therapy and clinical characteristics of the pneumonias. Furthermore, we do not have information on duration of ventilatory support, days in the intensive care unit, vaccinations or severity of the respiratory disease.

Third, regarding the characteristics of diabetes, we lack information on disease duration, complications, glycemic control and specific treatment.

Fourth, in most cases of a pneumonia acquired during the hospital admission pathogens are not cultured. This has also been reported in a recent investigation from the USA where of 110 HAP in only 46 (42%) a pathogen was reported.[@R6]

In conclusion, the incidence rates of the three types of pneumonia were higher in patients with T2DM than in patients with non-T2DM. IHM was significantly lower among patients with T2DM with VAP than matched patients without diabetes, and no differences in IHM were found for CAP or NV-HAP.

Higher mortality rates in patients with diabetes with any pneumonia type were associated with increasing age, presence of comorbidity and dialysis. In patients with VAP, the risk of IHM was higher among females.
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